
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion Inc demonstrates impressive momentum in its financial performance, highlighted by a 31% year-over-year increase in Q3 revenue, totaling $18,942, driven by a significant 89% rise in Nociscan report volumes. The company is aggressively investing in sales and marketing, as evidenced by a staggering 172% year-over-year increase in expenses, reflecting a strategic focus on expanding market presence and clinical trial support. Additionally, Aclarion's commercial agreements with prominent healthcare institutions across various states underscore its strong market position and the accelerating uptake of its Nociscan platform.
Bears say
Aclarion Inc faces significant challenges that contribute to a negative outlook on its stock, notably slower-than-expected traction with both surgeons and payers, which can hinder revenue growth. The company has consistently adjusted its FY25 EPS estimates downward, with the latest forecast showing an EPS of $(15.13) due to rising marketing and administrative expenses, indicating ongoing operational inefficiencies. Furthermore, risks surrounding liquidity, regulatory approvals, and competition compound concerns regarding Aclarion's ability to commercialize its Nociscan product effectively in a competitive healthcare market.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares